137 related articles for article (PubMed ID: 29692879)
1. Temporal Trends in Survival and Healthcare Costs in Patients with Multiple Myeloma in the United States.
Maiese EM; Evans KA; Chu BC; Irwin DE
Am Health Drug Benefits; 2018 Feb; 11(1):39-46. PubMed ID: 29692879
[TBL] [Abstract][Full Text] [Related]
2. Healthcare resource use and costs associated with chronic kidney disease in US private insurance patients with multiple myeloma.
Bhowmik D; Song X; Intorcia M; Kent ST; Shi N
J Oncol Pharm Pract; 2019 Jun; 25(4):855-864. PubMed ID: 29661050
[TBL] [Abstract][Full Text] [Related]
3. Health care resource utilization and costs among patients with multiple myeloma with exposure to double-class or triple-class multiple myeloma treatments: A retrospective US claims database analysis.
Yang J; Boytsov N; Carlson JJ; Barthold D
J Manag Care Spec Pharm; 2023 Aug; 29(8):917-926. PubMed ID: 37523320
[No Abstract] [Full Text] [Related]
4. All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States.
Asche CV; Singer ME; Jhaveri M; Chung H; Miller A
J Manag Care Pharm; 2010; 16(9):703-12. PubMed ID: 21067256
[TBL] [Abstract][Full Text] [Related]
5. Healthcare Costs of Multiple Myeloma Patients with Four or More Prior Lines of Therapy, Including Triple-Class Exposure in the United States.
Jagannath S; Joseph N; He J; Crivera C; Fu AZ; Garrett A; Shah N
Oncol Ther; 2022 Dec; 10(2):411-420. PubMed ID: 35579821
[TBL] [Abstract][Full Text] [Related]
6. Frequency of skeletal-related events and associated healthcare resource use and costs in US patients with multiple myeloma.
Nash Smyth E; Conti I; Wooldridge JE; Bowman L; Li L; Nelson DR; Ball DE
J Med Econ; 2016; 19(5):477-86. PubMed ID: 26671598
[TBL] [Abstract][Full Text] [Related]
7. Treatment Patterns and Associated Health Care Costs Before and After Treatment Initiation Among Pulmonary Arterial Hypertension Patients in the United States.
Burger CD; Ozbay AB; Lazarus HM; Riehle E; Montejano LB; Lenhart G; White RJ
J Manag Care Spec Pharm; 2018 Aug; 24(8):834-842. PubMed ID: 29436260
[TBL] [Abstract][Full Text] [Related]
8. Economic burden of skeletal-related events in patients with multiple myeloma: analysis of US commercial claims database.
Bhowmik D; Hines DM; Intorcia M; Wade RL
J Med Econ; 2018 Jun; 21(6):622-628. PubMed ID: 29571273
[TBL] [Abstract][Full Text] [Related]
9. Productivity loss outcomes and costs among patients with cholangiocarcinoma in the United States: an economic evaluation.
Parasuraman S; Thiel E; Park J; Teschemaker A
J Med Econ; 2023; 26(1):454-462. PubMed ID: 36883994
[TBL] [Abstract][Full Text] [Related]
10. Healthcare Costs Incurred by Patients with Multiple Myeloma Following Triple Class Exposure (TCE) in the US.
Jagannath S; Joseph N; He J; Crivera C; Fu AZ; Garret A; Shah N
Oncol Ther; 2021 Dec; 9(2):659-669. PubMed ID: 34694578
[TBL] [Abstract][Full Text] [Related]
11. Disease-related and all-cause health care costs of elderly patients with gout.
Wu EQ; Patel PA; Yu AP; Mody RR; Cahill KE; Tang J; Krishnan E
J Manag Care Pharm; 2008 Mar; 14(2):164-75. PubMed ID: 18331118
[TBL] [Abstract][Full Text] [Related]
12. Direct and Indirect Healthcare Resource Utilization and Costs Among Migraine Patients in the United States.
Bonafede M; Sapra S; Shah N; Tepper S; Cappell K; Desai P
Headache; 2018 May; 58(5):700-714. PubMed ID: 29446063
[TBL] [Abstract][Full Text] [Related]
13. Rheumatoid Arthritis-Interstitial Lung Disease in the United States: Prevalence, Incidence, and Healthcare Costs and Mortality.
Raimundo K; Solomon JJ; Olson AL; Kong AM; Cole AL; Fischer A; Swigris JJ
J Rheumatol; 2019 Apr; 46(4):360-369. PubMed ID: 30442831
[TBL] [Abstract][Full Text] [Related]
14. Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costs.
Meyers J; Yu Y; Kaye JA; Davis KL
Appl Health Econ Health Policy; 2013 Jun; 11(3):275-86. PubMed ID: 23677706
[TBL] [Abstract][Full Text] [Related]
15. Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus.
Menzin J; Korn JR; Cohen J; Lobo F; Zhang B; Friedman M; Neumann PJ
J Manag Care Pharm; 2010 May; 16(4):264-75. PubMed ID: 20433217
[TBL] [Abstract][Full Text] [Related]
16. Characterizing downstream healthcare resource utilization and costs based on prior utilization patterns of immediate-release hydrocodone.
Ben-Joseph R; Bell JA; Chitnis A; Kansal A; Holly P; Paramore C; Wild H
J Med Econ; 2016; 19(2):169-80. PubMed ID: 26451633
[TBL] [Abstract][Full Text] [Related]
17. Healthcare Utilization and Direct Costs in Patients with Ankylosing Spondylitis Using a Large US Administrative Claims Database.
Walsh JA; Song X; Kim G; Park Y
Rheumatol Ther; 2018 Dec; 5(2):463-474. PubMed ID: 30121826
[TBL] [Abstract][Full Text] [Related]
18. Direct health care costs associated with COVID-19 in the United States.
DeMartino JK; Swallow E; Goldschmidt D; Yang K; Viola M; Radtke T; Kirson N
J Manag Care Spec Pharm; 2022 Sep; 28(9):936-947. PubMed ID: 35722829
[No Abstract] [Full Text] [Related]
19. Excess healthcare costs in patients with autosomal dominant polycystic kidney disease by renal dysfunction stage.
Gagnon-Sanschagrin P; Liang Y; Sanon M; Oberdhan D; Guérin A; Cloutier M
J Med Econ; 2021; 24(1):193-201. PubMed ID: 33464936
[TBL] [Abstract][Full Text] [Related]
20. Trends in overall survival and costs of multiple myeloma, 2000-2014.
Fonseca R; Abouzaid S; Bonafede M; Cai Q; Parikh K; Cosler L; Richardson P
Leukemia; 2017 Sep; 31(9):1915-1921. PubMed ID: 28008176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
